Skip to content

Kintsugi Voice Device Pivotal Study

Kintsugi Voice Device SCID-5 Pivotal Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06809907
Enrollment
1600
Registered
2025-02-05
Start date
2025-03-27
Completion date
2026-02-28
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Depression Mild, Depression Moderate, Depression Severe

Brief summary

A prospective, single arm, non-randomized, pivotal clinical validation study to evaluate the ability of the Kintsugi Voice Device (the Device) to aid clinical assessment for depression by comparing its output with a diagnosis made by a clinician using the Structured Clinical Interview for DSM-5 (SCID-5-RV) for up to 1000 English speaking adult patients ages 22 and older living in the United States. Recruitment will occur for 1 year and participation will be for up to 2 weeks

Interventions

The Kintsugi Voice Device is intended to be used to screen for the presence of voice signals consistent with a current moderate to severe depressive episode in patients aged 22 and older. The device is intended to be used by care providers licensed to screen for depression and in settings where the screening for depression occurs. The device is neither to be used in lieu of a complete patient evaluation nor to supplant any of the clinician's standard assessments for the screening or diagnosis of depression. The Kintsugi Voice Device is comprised of a software API and machine learning model that utilizes recorded voice samples as inputs and outputs the detection of signals consistent with current moderate to severe depressive episode as outputs.

Sponsors

Kintsugi Mindful Wellness, Inc.
Lead SponsorINDUSTRY
Kolby Walker, DO
CollaboratorUNKNOWN
Sonar Strategies
CollaboratorUNKNOWN
Brittany Kimble
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Age \>22 at the time of informed consent Self-reported disruption to activities of daily living (e.g. missed scheduled healthcare appointments, unable to concentrate on tasks like reading, working, or completing daily activities, or difficult completing activities such as exercise, diet, or recreation) Access to a laptop, smartphone, tablet, or other device with a functioning microphone and access to the Internet Stated willingness to be video and audio recorded as part of the study Stated willingness to comply with all study procedures and availability for the duration of the study Functional English capacity in the home environment Availability for the duration of the study Resides in the United States at the time of consent and during completion of study \-

Exclusion criteria

* Participants with at least one of the following conditions will be excluded: Any impairment that impacts their ability to speak and/or use a computer to complete online surveys and/or a virtual clinician assessment (E.g., visual impairment, motor impairment, and/or hearing impairment) Any lifetime history of neurological disease that impacts their ability to speak and/or use a computer to complete online surveys and/or a virtual clinician assessment (E.g., Central Nervous System disorders, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and/or Parkinson's Disease) Any lifetime history of Stroke, cognitive defect (E.g., dementia or Alzheimer's disease), and/or Traumatic Brain Injury Presence of voice disorders that impacts their ability to speak (E.g., acute or chronic laryngitis, vocal cord paresis or paralysis, or spasmodic dysphonia) Past or active heavy smokers (an average of \>20 cigarettes per day) Subjects who have previously participated in any Kintsugi-sponsored study

Design outcomes

Primary

MeasureTime frameDescription
1. Sensitivity and Specificity of Kintsugi Voice Device Relative to the SCID-5Day 1Achieve a composite lower bound of sensitivity greater than or equal to 70% and specificity greater than or equal to 70% for the KV Device relative to the high diagnostic confidence clinical reference standard as defined in Section 7.4.1 for which the device provides a result

Secondary

MeasureTime frameDescription
Adjudicated Samples Sensitivity and SpecificityDay 1Evaluate sensitivity and specificity for all adjudicated samples for which the device provides a result
PPV and NPV EvaluationDay 1Evaluate the Positive Predictive Value (PPV) and Negative Predictive Value (NPV)
Subgroup Analysis (Sensitivity and Specificity)Day 1Perform subgroup analyses including but not limited to age, race, and ethnicity
Indeterminate Result AnalysisDay 1Measurement of the proportion of all participants for whom the device provides no result

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026